The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome
| Autor: | Alexandros Sotiriadis, Konstantinos Dinas, Konstantinos Tziomalos, Panagiotis Chatzis, Georgios C. Pratilas, Vasileios Makris |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Population lcsh:Medicine 030209 endocrinology & metabolism Management of obesity 03 medical and health sciences 0302 clinical medicine Weight loss Internal medicine mental disorders Weight Loss medicine Humans Obesity education Bupropion Orlistat education.field_of_study 030219 obstetrics & reproductive medicine business.industry Liraglutide lcsh:R Hyperandrogenism General Medicine medicine.disease Polycystic ovary Naltrexone Drug Combinations Endocrinology Androgens Female Anti-Obesity Agents medicine.symptom Insulin Resistance business medicine.drug Polycystic Ovary Syndrome |
| Zdroj: | Folia Medica, Vol 60, Iss 4, Pp 512-520 (2018) |
| ISSN: | 1314-2143 |
| Popis: | Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age. Obesity is frequently present in these patients and plays a key role in the pathogenesis of both the endocrine and metabolic abnormalities of the syndrome, particularly infertility, hyperandrogenism and insulin resistance (IR). Diet and exercise is the mainstay of management of obesity in patients with PCOS. In contrast, the eff ects of antiobesity agents on weight and on the obesityrelated characteristics of the syndrome remain unclear. The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population. Several studies reported that orlistat induces weight loss, improves IR and reduces androgen levels in PCOS. In contrast, data regarding the eff ects of the dose of liraglutide that is approved for the treatment of obesity (3 mg od) are very limited. Liraglutide 1.2-1.8 mg od results in weight loss in these patients but does not aff ect IR or androgen levels. Finally, there are no studies that evaluated naltrexone/bupropion in patients with PCOS and early studies reported conflicting results regarding the eff ects of naltrexone monotherapy on weight, IR and androgen levels. In conclusion, orlistat appears to have a role in the management of overweight and obese patients with PCOS whereas more studies are needed to clarify the role of liraglutide and naltrexone/bupropion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|